

Anti-hPD1-Ni-hIgA2

Monoclonal human IgA2 antibody against human PD-1

Catalog # hpd1ni-mab7

For research use only, not for diagnostic or therapeutic use

Version # 15K11-MM

PRODUCT INFORMATION

Content: 100 µg anti-hPD1-Ni-hIgA2, purified antibody, provided azide-free and lyophilized.

Specificity: Programmed cell death 1 (PD-1) receptor

Isotype: Human IgA2

Source: CHO cells

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Antibody resuspension

Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml.

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year.

- Reconstituted antibody is stable for 1 month when stored at 4 °C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding of Anti-hPD1-Ni-hIgA2 to human PD1 has been tested using flow cytometry.

- The complete sequence of this antibody has been verified.

- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hPD1-Ni-hIgA2 features the constant region of the human IgA2 isotype and the variable region of nivolumab. Nivolumab is a fully human IgG4 (S228P) monoclonal antibody that targets the PD-1 receptor found on activated T cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 negatively regulates T cell activation thereby preventing autoimmunity¹. Under pathological conditions, cancer cells produce PD-L1 (programmed cell death 1 ligand 1), the agonist that binds and activates PD-1. Activated PD-1 enables the cancer cells to evade the immune system. Nivolumab binds and blocks the activation of the PD-1 receptor, thereby resulting in the activation of T cells and cell-mediated immune responses^{2, 3}. This antibody contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules. Nivolumab has been approved by the FDA for the treatment of melanoma and metastatic squamous non-small cell lung cancer (NSCLC).

Anti-hPD1-Ni-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

1. **McDermott D. & Atkins M. 2013.** PD-1 as a potential target in cancer therapy. *Cancer Med.* 2(5): 662-673. 2. **Wang C. et al., 2014.** In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. *Cancer Immunol Res.* 2014 Sep;2(9):846-56. 3. **Gunturi A. & McDermott DF, 2015.** Nivolumab for the treatment of cancer. *Expert Opin Investig Drugs.* 24(2):253-60.

ANTIBODY ISOTYPE FAMILY

For your research, InvivoGen provides an anti-hPD1-Ni isotype family. This family consists of monoclonal antibodies comprising the variable region of nivolumab, and the constant region of three different human isotypes; IgG1, IgG4 and IgA2. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

Isotype	Description
Human IgG1	Most abundant IgG present in serum High CDC, high ADCC
Human IgG4	Least common IgG present in serum No CDC, low ADCC
Human IgA2	Major class in secretions, oligomeric forms, highly resistant to enzymatic degradation. No CDC, low ADCC

RELATED PRODUCTS

Product	Catalog Code
Anti-hPD1-Ni-hIgG1	hpd1ni-mab1
Anti-hPD1-Ni-hIgG4S228P (Nivolumab)	hpd1ni-mab14

Other antibody isotype families are available, such as Anti-hCD20, Anti-HER2 and Anti-β-Gal (control).

For more information visit www.invivogen.com/antibody-isotypes

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com